Eurycomanone inhibits osteosarcoma growth and metastasis by suppressing GRP78 expression

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Osteosarcoma (OS) is an aggressive bone cancer with high metastatic potential, particularly to the lungs.
• Eurycoma longifolia Jack, a traditional herbal medicine, contains eurycomanone (EUR), known to inhibit cancer cell proliferation.
• GRP78 is highly expressed in OS and linked to poor patient prognosis.

Purpose of the Study:

• To investigate the anti-cancer effects of eurycomanone (EUR) on osteosarcoma (OS) growth and metastasis.
• To elucidate the molecular mechanisms underlying EUR's action on OS, focusing on GRP78.
• To evaluate EUR's therapeutic potential for osteosarcoma treatment.

Main Methods:

• In vitro assays assessed cell proliferation, apoptosis, migration, invasion, and angiogenesis.
• Western blotting and qRT-PCR analyzed GRP78, apoptosis, and angiogenesis markers.
• In vivo studies in mouse models evaluated tumor growth, metastasis, and toxicity.

Main Results:

• Eurycomanone (EUR) significantly inhibited OS cell proliferation, migration, invasion, and angiogenesis in vitro.
• EUR treatment reduced GRP78 expression by decreasing its mRNA stability and transcription.
• In vivo experiments confirmed EUR's ability to suppress tumor growth and metastasis in mouse models.

Conclusions:

• Eurycomanone (EUR) effectively inhibits osteosarcoma growth and metastasis.
• The mechanism involves the downregulation of GRP78 expression via reduced mRNA stability and transcription.
• EUR presents a promising novel therapeutic agent for osteosarcoma treatment.